Stockreport

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Evolus, Inc.  (EOLS) 
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
PDF The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lin [Read more]